NYSEAMERICAN:TRXC - TransEnterix Stock Price, Price Target & More

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its quarterly earnings results on Tuesday, May, 8th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The medical instruments supplier had revenue of $4.77 million for the quarter, compared to analyst estimates of $3.81 million. TransEnterix had a negative return on equity of 137.69% and a negative net margin of 21,045.36%. View TransEnterix's Earnings History.

3 Wall Street analysts have issued 1-year target prices for TransEnterix's shares. Their predictions range from $4.00 to $5.50. On average, they expect TransEnterix's share price to reach $4.75 in the next year. This suggests that the stock has a possible downside of 8.7%. View Analyst Ratings for TransEnterix.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

TransEnterix saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 31,775,708 shares, an increase of 12.4% from the June 15th total of 28,275,314 shares. Based on an average daily volume of 14,889,329 shares, the days-to-cover ratio is currently 2.1 days. Currently, 20.5% of the shares of the stock are sold short. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), CRH Medical (CRH), CRH Medical (CRHM), Tristel (TSTL), TSO3 (TOS), Clover (CLV), Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), IsoRay (ISR), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX) and Relevium Technologies (RLV).

Headlines about TRXC stock have trended somewhat positive on Monday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TransEnterix earned a news sentiment score of 0.12 on Accern's scale. They also assigned media stories about the medical instruments supplier an impact score of 46.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

TransEnterix's stock is owned by many different of institutional and retail investors. Top institutional investors include Prospera Financial Services Inc (0.04%) and Amalgamated Bank (0.01%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for TransEnterix.

TRXC stock was bought by a variety of institutional investors in the last quarter, including Prospera Financial Services Inc and Amalgamated Bank. Company insiders that have bought TransEnterix stock in the last two years include Andrea Biffi, Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $5.20.

TransEnterix has a market capitalization of $354.65 million.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.